Bertrand D van Zelst
Overview
Explore the profile of Bertrand D van Zelst including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
204
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schoenmakers S, Li L, Kluivers A, Broekhuizen M, Harhangi M, Danser A, et al.
Br J Clin Pharmacol
. 2025 Mar;
PMID: 40083164
Aims: To enhance understanding of betamethasone and its metabolites' pharmacokinetics in pregnancy, specifically early-onset pre-eclampsia, through a population pharmacokinetic model. Additionally, to investigate the placental metabolism and transfer of betamethasone...
2.
van Beijsterveldt I, van Zelst B, Dorrepaal D, van den Berg S, Hokken-Koelega A
Eur J Endocrinol
. 2024 Mar;
190(4):338-346.
PMID: 38554392
Importance: Poly- and perfluoroalkyl substances (PFASs) are nondegradable, man-made chemicals. They accumulate in humans with potential harmful effects, especially in susceptible periods of human development, such as the first months...
3.
Wenstedt E, van Zelst B, Paula N, van den Berg S
Clin Chem Lab Med
. 2023 Dec;
62(7):e151-e154.
PMID: 38105246
No abstract available.
4.
Ho C, Hoad K, Cooke B, Andersen T, Graham P, van den Berg S, et al.
Clin Chem Lab Med
. 2023 Dec;
62(5):911-918.
PMID: 38063179
Objectives: Interference from isomeric steroids is a potential cause of disparity between mass spectrometry-based 17-hydroxyprogesterone (17OHP) results. We aimed to assess the proficiency of mass spectrometry laboratories to report 17OHP...
5.
van Hulst A, Grootenhuis M, Verwaaijen E, van Litsenburg R, Li L, van Zelst B, et al.
JCO Precis Oncol
. 2023 Jun;
7:e2200678.
PMID: 37343203
Purpose: Dexamethasone, the preferred corticosteroid in most treatment protocols for pediatric acute lymphoblastic leukemia (ALL), can induce undesirable side effects. Neurobehavioral and sleep problems are frequently reported, but the interpatient...
6.
van Beijsterveldt I, van Zelst B, de Fluiter K, van den Berg S, van der Steen M, Hokken-Koelega A
Environ Int
. 2022 May;
164:107274.
PMID: 35524998
Background And Aims: Per- and polyfluoroalkyl substances (PFAS) are non-degradable, man-made-chemicals with an elimination half-life of multiple years, causing accumulation in the environment and humans with potential harmful effects. However,...
7.
van Beijsterveldt I, van Zelst B, van den Berg S, de Fluiter K, van der Steen M, Hokken-Koelega A
Environ Int
. 2021 Dec;
160:107068.
PMID: 34968992
Background And Aims: Per- and polyfluoroalkyl substances (PFAS) are a potential hazard for public health. These man-made-chemicals are non-degradable with an elimination half-life of multiple years, causing accumulation in the...
8.
Gosselt H, Griffioen P, van Zelst B, Oosterom N, de Jonge R, Heil S
Epigenetics
. 2020 Jul;
16(1):45-53.
PMID: 32614650
Background: Epigenetic markers are often quantified and related to disease in stored samples. While, effects of storage on stability of these markers have not been thoroughly examined. In this longitudinal...
9.
Oosterom N, de Jonge R, Smith D, Pieters R, Tissing W, Fiocco M, et al.
PLoS One
. 2019 Sep;
14(9):e0221591.
PMID: 31527879
Background: Methotrexate (MTX) is an important anti-folate agent in pediatric acute lymphoblastic leukemia (ALL) treatment. Folinic acid rescue therapy (Leucovorin) is administered after MTX to reduce toxicity. Previous studies hypothesized...
10.
Gosselt H, van Zelst B, de Rotte M, Hazes J, de Jonge R, Heil S
Arthritis Res Ther
. 2019 Jun;
21(1):157.
PMID: 31242943
Background: Low-dose methotrexate (MTX) is the first-line therapy in early rheumatoid arthritis (eRA). Up to 40% of eRA patients do not benefit from MTX therapy. MTX has been shown to...